He will be speaking on the use of psychedelics in treating obesity and eating disorders.
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2021) - NeonMind Biosciences Inc. (CSE: NEON) (FSE: 6UF) (“NeonMind”), a psychedelic drug development company, is pleased to announce that Robert Tessarolo, President & Chief Executive Officer, will be speaking at the Psychedelic, Therapeutics, & Drug Development Conference that will be held virtually from May 4-6. He will be speaking on the use of psychedelics in treating obesity and eating disorders.
Figure 1: NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference
To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/7646/78904_neon2.jpg
The conference will unite the top business and academic leaders including Frederick Barrett, Ph.D., Assistant Professor of Psychiatry & Behavioral Sciences at Johns Hopkins School of Medicine, to discuss, analyze, and share intelligence on regulatory changes and other challenges on psychedelic research for treatment of a myriad of serious chronic medical conditions.
“The Psychedelic, Therapeutics, and Drug Development Conference is an excellent opportunity for NeonMind to share our vision and progress with other industry leaders and key stakeholders,” said Rob Tessarolo. “I also look forward to listening to the many great experts and innovators who will discuss a number of regulatory and policy changes that will help unlock the full health potential of this emerging field.”
NeonMind is currently advancing two (2) psilocybin-based drug development programs aimed at treating obesity. Psychedelic therapy has the potential to institute long term positive behaviours that may aid in weight loss and its maintenance, and psilocybin in low doses may help control appetite and satiety.
“There is a clear need for new treatments, new solutions, new approaches for the obesity epidemic and psychedelics are well positioned to offer new therapeutic breakthroughs,” said Rob Tessarolo. “NeonMind will continue to advance our important research and be a leader in commercialization following regulatory approval.”
About NeonMind Biosciences Inc.
NeonMind is engaged in research and development of products to optimize human health and performance. NeonMind has two divisions, a pharmaceutical division engaged in drug development of psychedelic compounds, and a consumer products division with a focus on mushroom infused products. NeonMind’s consumer division currently sells 4 NeonMind branded coffee products in Canada through NeonMind’s direct to consumer e-commerce platform, and it has plans to launch products in Canada as natural health products once Health Canada approves its recent applications. NeonMind also plans to launch dietary supplements in the United States this spring.
In its pharmaceutical division, NeonMind has two distinct psilocybin drug development programs targeting obesity. NeonMind’s first drug candidate aims to use synthetic psilocybin to enhance a patient’s ability to adopt behaviours that cause weight loss and maintain that loss through psychedelic-assisted cognitive therapy. The second drug candidate offers low dose synthetic psilocybin as a treatment to suppress appetite.
NeonMind’s first drug candidate employs psilocybin as an agonist to the serotonin receptor 5- HT2A, which is involved in the hallucinogenic effect of psychedelics, and the second drug candidate employs low-dose psilocybin as an agonist to the 5-HT2C receptor, which controls appetite.
For more information on NeonMind, go to www.NeonMindBiosciences.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor Relations:
Edge Communications
invest@neonmind.com
Tel: 1-866-318-6874
Renmark Financial Communications Inc.
Melanie Barbeau
mbarbeau@renmarkfinancial.com
Tel: 416-644-2020 or 212-812-7680
Media Inquiries:
Exvera Communications Inc.
brittany@exvera.com
The Canadian Securities Exchange has not reviewed, approved nor disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind’s future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”,"estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on NeonMind’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s drug development plans, its ability to retain key personnel, and its expectation as to the development of its intellectual property and other steps in its preclinical and clinical drug development constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/78904
